• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Postoperative outcomes and recurrence patterns of intermediate-stage hepatocellular carcinoma dictated by the sum of tumor size and number

    2022-12-01 01:45:42XinShengHuHuiYuanYangChaoLengZhiWeiZhang
    World Journal of Gastroenterology 2022年44期

    Xin-Sheng Hu,Hui-Yuan Yang, Chao Leng,Zhi-Wei Zhang

    Abstract

    Key Words: Hepatocellular carcinoma; Multinodular; Intermediate-stage; Liver resection; Recurrence pattern; Prognosis

    INTRODUCTION

    As the sixth most common cancer globally, primary liver cancer accounted for 906,000 newly confirmed cancer cases and 830,000 cancer-related deaths worldwide in 2020, of which 75%-85% were hepatocellular carcinoma (HCC)[1].

    Barcelona Clinic Liver Cancer (BCLC) staging system, which was proposed in 1999, has been widely used to guide treatment decisions in patients with HCC[2,3]. The 2022 version of the BCLC strategy recommends liver transplantation (LT), transarterial chemoembolization (TACE), and systemic therapy,respectively, for BCLC intermediate-stage HCC patients based on their expected survival time[4].

    In addition, emerging studies have suggested that liver resection (LR) may also be a good treatment option for BCLC-B HCC patients[5,6]. Nevertheless, the subgroups of BCLC-B HCC patients who would truly benefit from LR have yet to be defined. Several previous studies found that some BCLC-B HCC patients undergoing LR had favorable long-term overall survival (OS) rates (5-year OS rates: 50%-75%);however, these selected patients still had high postoperative recurrence rates (2-year recurrence rate: ≥50%), which means that many of these patients had good recurrence-to-death survival (RTDS)[7,8]. Both recurrence patterns and treatments after recurrence can affect the RTDS of HCC patients who develop recurrence after LR[9-11]. However, previous studies did not analyze the main reasons why these selected patients had good RTDS, which may affect the judgment of the role of LR in these patients[7,8].

    In this study, we retrospectively included patients undergoing curative LR for BCLC stage A or B multinodular HCC (MNHCC) and stratified the BCLC-B patients by the sum of tumor size and number(N + S), which combines the two main prognostic factors of BCLC-B patients into a continuous variable[7,8]. BCLC-B patients more suitable for LR were identified by comparing the outcomes, recurrence patterns, and treatments after recurrence in BCLC-B patients in each subgroup with those in BCLC-A patients.

    MATERIALS AND METHODS

    Patients

    We enrolled BCLC stage A or B MNHCC patients who underwent curative LR in Tongji Hospital from January 2010 to May 2018. The inclusion criteria were: (1) MNHCC pathologically diagnosed with two or more nodules, in which lesions less than 1 cm in diameter and less than 2 cm away from the main nodule were defined as satellite nodules[12]; (2) Curative resection, defined as complete macroscopic removal of all tumors with negative histologic resection margins for the tumors (R0 resection)[13,14];and (3) No preoperative anticancer treatment other than TACE. The exclusion criteria were: (1) Recurrent HCC or combined HCC and cholangiocarcinoma; and (2) Complicated with other malignancies.

    Data collection

    Patient data at the time of initial hepatectomy including sex, age, body mass index, hepatitis B antigen status, liver function, tumor characteristics, surgical procedure, and preoperative treatment were recorded. Liver function in this study was classified by the albumin-bilirubin score[15]. Maximum tumor size was defined as the maximum diameter of the largest tumor. Microvascular invasion was defined as tumor within a vascular space lined by endothelium that was visible only on microscopy[16].In addition, the recurrence patterns, which consisted of recurrence time and tumor characteristics at the time of recurrence, and treatments after recurrence in those patients who developed recurrence during follow-up were also recorded. Recurrence time was defined as the time between initial LR and the first recurrence.

    Initial hepatectomy

    In our center, we routinely estimated the residual liver volume in MNHCC patients before hepatectomy,and only patients with residual liver volume of more than 40% of the standard liver volume (for patients with liver cirrhosis) or more than 30% (for patients without liver cirrhosis) would receive LR[17,18]. The decision to perform anatomical or non-anatomical hepatectomy depended largely on the tumor distribution, and major resection was defined as the resection of three or more Couinaud liver segments[19]. Intraoperative ultrasound was routinely used to locate the tumor and screen the nodules.All nodules were completely resected intraoperatively and negative margin was determined according to postoperative pathology.

    Follow-up

    Patients were followed every month with measurement of serum alpha-fetoprotein (AFP), chest radiography and ultrasound or computed tomography (CT) or magnetic resonance imaging (MRI) in the first 6 mo after discharge from hospital, and every 3-6 mo thereafter. When HCC recurrence was confirmed by CT or MRI, patients were treated with repeated hepatectomy, ablation, TACE or systemic therapy. Follow-up was terminated on May 15, 2022.

    Recurrence-free survival (RFS) was calculated from the date of hepatectomy until recurrence or last follow-up. OS was defined as the time from LR to death or last follow-up, and RTDS was defined as the time from recurrence to death or last follow-up.

    Statistical analysis

    Continuous variables were presented as mean ± SD or median (interquartile range; IQR). Categorical variables were described by frequency and percentage. In the comparison of different subgroups,continuous variables were compared using the Student’stor Mann-WhitneyUtest, and categorical variables using theχ2or Fisher’s exact test, as appropriate. Survival was analyzed by the Kaplan-Meier method, and survival curves were compared by the log-rank test. Univariate and multivariate analyses were based on the Cox proportional analysis. Variables withPvalues less than 0.1 identified by the univariate analysis were included in multivariate analysis. The cutoff value of N + S was determined by X-tile, a bioinformatics tool produced by Camp and colleagues[20]. The area under receiver operating characteristic (ROC) curve (AUC) was compared using DeLong test[21].P< 0.05 was considered to indicate statistical significance. Both SPSS (version 23.0, SPSS, Inc., Chicago, IL, United States) and MedCalc software (version 20.115, MedCalc Software, Ostend, Belgium) were used for the analysis.

    RESULTS

    Variables and outcomes of the entire cohort

    A total of 143 patients who underwent curative LR for BCLC stage A or B MNHCC were enrolled. Their mean age was 52.1 years and most patients were male (n= 134, 93.7%) and were hepatitis B surface antigen positive (n= 131, 91.6%). Median maximum tumor size in the entire cohort was 5.6 cm (IQR:3.4-7.6) and tumor number in the vast majority of patients was ≤ 3 (n= 136, 95.1%). Overall, 17.5% (n=25) of patients had BCLC-A MNHCC, and 82.5% (n= 118) had BCLC-B MNHCC (Table 1).

    After a median follow-up of 54 mo (IQR 27-79), 5-year OS and RFS after R0 resection in all patients were 60.2% and 23.2%, respectively. Of note, BCLC-B patients had worse 5-year OS (57.2%vs74.1%,P=0.028, Supplementary Figure 1A) and RFS (19.4%vs41.6%,P= 0.002, Supplementary Figure 1B).

    Stratification of BCLC-B patients based on N + S

    Among patients undergoing LR for BCLC-B HCC, the median maximum tumor size was 6.2 cm (IQR:4.1-8.4) and tumor number in 111 (94.1%) patients was ≤ 3. Of note, 43.2% (n= 51) of patients had bilateral disease and 14.4% (n= 17) of patients underwent TACE before initial LR (Table 1).

    Using the X-tile program[20], patients with BCLC-B HCC were divided into two groups by N + S:BCLC-B1 (≤ 10,n= 83, 70.3%), BCLC-B2 (> 10,n= 35, 29.7%) (Supplementary Figure 2).

    The prognostic ability of N + S and the rationality of the cut-off value of 10 were then verified by time-dependent ROC curves and Cox-regression analysis. The AUCs for 3-year and 5-year OS in BCLCB patients were 0.650 and 0.646, respectively, for N + S, and 0.640 and 0.643, respectively, for stratification according to N + S (Figure 1). Multivariate analysis showed that N + S > 10 was an independent risk factor for OS [hazard ratio (HR) 2.996, 1.779 to 5.045; P < 0.001] (Table 2) and RFS (HR 1.657, 1.057 to 2.596;P= 0.028) (Table 3) in BCLC-B patients.

    In addition, we compared the predictive accuracy of N + S with those of tumor burden score (TBS)and total tumor volume (TTV), both of which were previous prognostic models based on tumor size and number of HCC patients[22,23]. The results showed that the AUCs of N + S at 3 and 5 years were both similar to those of TBS (3-year AUC, 0.650vs0.646,P= 0.552; 5-year AUC, 0.646vs0.643,P= 0.762) and TTV (3-year AUC, 0.650vs0.628,P= 0.171; 5-year AUC, 0.646vs0.636,P= 0.535) (Figure 1).

    Comparison of the clinical characteristics, OS, and RFS among BCLC-A, BCLC-B1 and BCLC-B2 patients

    Clinical characteristics, OS and RFS of patients with BCLC-B1, BCLC-B2, and BCLC-A were compared(Figure 2, Supplementary Table 1). The results showed that BCLC-B2 patients had a higher serum AFP level and a larger proportion of bilateral tumor distribution, compared to patients with BCLC-A and BCLC-B1. With an increase in N + S, the maximum tumor size gradually increased, and a larger proportion of patients underwent major resection (Supplementary Table 1).

    Both BCLC-A patients and BCLC-B1 patients had good 5-year OS (74.1%vs67.4%,P= 0.250), which was better than that in BCLC-B2 patients (74.1%vs33.6%,P< 0.001; 67.4%vs33.6%,P< 0.001)(Figure 2A). Compared with BCLC-A patients, BCLC-B1 patients had a worse RFS (median RFS: 19 movs48 mo;P= 0.022), which was better than that in BCLC-B2 patients (median RFS: 19 movs7 mo;P<0.001) (Figure 2B).

    Table 1 Characteristics of patients with Barcelona Clinic Liver Cancer stage A or B multinodular hepatocellular carcinoma, n (%)

    Comparison of recurrence patterns, treatments after recurrence, and RTDS in BCLC-A, BCLC-B1 and BCLC-B2 patients

    During follow-up, 14 (56%) BCLC-A, 66 (79.5%) BCLC-B1 and 34 (97.1%) BCLC-B2 patients developed recurrences (P< 0.001). Nine BCLC-B1 and 4 BCLC-B2 patients who lacked information on tumor characteristics at the time of recurrence and treatments after recurrence were excluded from the analysis. Ultimately, 14 BCLC-A, 57 BCLC-B1 and 30 BCLC-B2 patients with recurrence were included in the analysis. The recurrence patterns and treatments after recurrence in these patients are summarized in Supplementary Table 2.

    Compared with BCLC-A and BCLC-B1 patients, BCLC-B2 patients had a shorter recurrence time and a higher proportion of recurrence with macrovascular invasion and/or extrahepatic metastasis.However, there were no significant statistical differences in recurrence patterns and treatment after recurrence between BCLC-B1 and BCLC-A patients. Fewer BCLC-B2 patients underwent curative treatments after recurrence than BCLC-A patients, but the treatment after recurrence was similar between BCLC-B2 patients and BCLC-B1 patients (Supplementary Table 2).

    Both BCLC-B1 and BCLC-A patients had good RTDS (median RTDS: Not reached,vs49 mo for BCLC-B1 and BCLC-A patients, respectively;P= 0.599), while BCLC-B2 patients had a worse RTDS (16 movsnot reached,P< 0.001; 16 movs49 mo,P= 0.042) (Figure 3).

    Table 2 Univariate and multivariate analysis of overall survival in patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

    Independent risk factors for RTDS

    We further conducted a multivariate analysis of the factors affecting RTDS of BCLC stage A or B MNHCC patients undergoing LR. Multivariate analysis showed that initial tumor with BCLC-B2 (N + S> 10) (HR 2.696, 1.468 to 4.953;P= 0.001), recurrence within 2-year (HR 4.353, 1.024 to 18.503;P= 0.046),recurrent tumor number > 3 (HR 3.247, 1.629 to 6.474;P= 0.001), recurrence with macrovascular invasion and/or extrahepatic spread (HR 2.894, 1.458 to 5.746;P= 0.002) and noncurative treatments after recurrence (HR 2.423, 1.209 to 4.854;P= 0.013) were independent risk factors for RTDS(Supplementary Table 3).

    DISCUSSION

    The role of LR in BCLC-B HCC patients is unclear. Although the latest BCLC staging system still does not recommend LR for BCLC-B patients, the results of emerging studies have indicated that LR resulted in a good 5-year OS for BCLC-B HCC patients[4-6]. In this study, patients who underwent LR for BCLCB HCC had an overall 5-year OS rate of 57.2%, which demonstrated that LR was a good treatment option in these patients.

    To select BCLC-B patients more suitable for LR, we stratified these patients according to N + S, which has been used to select HCC patients who are more suitable for LT and for TACE[24,25]. In fact,Matsukumaet al[26] suggested that N + S was a good prognostic factor for BCLC-B HCC patients undergoing hepatectomy. The present study increased the cutoff point of N + S from 8 to 10, which may be related to different study cohorts and different calculation methods used for the cutoff value[26].Nevertheless, the results of this study and in the study by Matsukumaet al[26] demonstrated that N + S could predict the recurrence and OS of BCLC-B HCC patients undergoing hepatectomy. In addition, the present study showed that N + S had a predictive accuracy similar to TBS and TTV in predicting OS inBCLC-B patients. However, compared with the complicated calculation of TBS and TTV, the calculation of N + S is simpler and more suitable for clinical application.

    Table 3 Univariate and multivariate analysis of recurrence-free survival in patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma

    Previous studies have focused on the OS when selecting BCLC-B patients for LR, and ignored that those selected patients still had a high postoperative recurrence rate[7,8]. In order to demonstrate that the selected BCLC-B HCC patients truly benefit from LR rather than remedial treatments after recurrence, and to better understand the tumor characteristics of the selected patients, we compared not only the OS and RFS, but also the RTDS, recurrence patterns, and treatments after recurrence.

    In the present study, BCLC-B1 (BCLC-B with N + S ≤ 10) HCC patients were considered as BCLC-B HCC patients who likely benefitted most from LR. Although BCLC-B1 HCC patients were still more likely to develop recurrence after LR than BCLC-A MNHCC patients, these BCLC-B1 patients had mild recurrence pattern, good RTDS and excellent OS similar to BCLC-A MNHCC patients.

    However, BCLC-B2 (BCLC-B with N + S > 10) HCC patients not only had a high postoperative recurrence rate, but also an aggressive recurrence pattern. Although the treatment after recurrence was similar between BCLC-B2 patients and BCLC-B1 patients, the BCLC-B2 patients still had a worse RTDS.The long-term OS of BCLC-B2 patients undergoing LR is not satisfactory.

    To the best of our knowledge, this study is the first to demonstrate that N + S could predict not only prognosis in BCLC-B HCC patients, but also the recurrence patterns and RTDS in these patients.

    In addition, it is interesting to note that patients with BCLC-B1 HCC had worse RFS but comparable OS than patients with BCLC-A MNHCC in this study. In fact, previous studies comparing LTvsLR in HCC patients found a similar phenomenon. These studies showed that although patients receiving LR had a higher rate of postoperative recurrence, the 5-year OS between LR and LT was comparable[27,28].Previous studies have suggested that the reasons for this phenomenon may be related to noncancerous death in the LT group and treatment after recurrence in the LR group, and our results suggest that it may also be related to the recurrence patterns after LR.

    As a single-center retrospective study, the present study has some limitations. Firstly, the sample size was small, which may have affected the accuracy of the results. Secondly, there was a lack of comparison of treatment options other than LR. Some patients with BCLC-B HCC and N + S ≤ 10 would meet the ‘Extended Liver Transplant criteria’, and the best treatment option for these patients remains to be explored[29]. Finally, the results of this study need to be verified by an external cohort.

    CONCLUSION

    N + S is a good measure that could predict the OS, RFS, RTDS and recurrence patterns in BCLC-B HCC patients undergoing LR. In particular, BCLC-B patients with N + S ≤ 10 had survivals similar to those of BCLC-A MNHCC patients. Given the computational simplicity of N + S, it is worth exploring the application of N + S to guide decision-making in the treatment of BCLC-B patients.

    ARTICLE HIGHLIGHTS

    Research motivation

    There is a lack of studies on whether the sum of tumor size and number (N + S) can be used to select BCLC-B patients who are more suitable for LR. The effect of recurrence patterns on long-term survival in BCLC-B patients undergoing LR is also poorly explored.

    Research objectives

    The present study aimed to identify BCLC-B patients more suitable for LR and to further analyze the reasons why these patients could benefit from LR.

    Research methods

    BCLC stage A or B multinodular HCC (MNHCC) patients undergoing curative hepatectomy were enrolled. Overall survival (OS), recurrence-free survival (RFS), recurrence-to-death survival (RTDS),recurrence patterns, and treatments after recurrence in BCLC-B patients in each subgroup according to N + S were compared with those in BCLC-A patients.

    Research results

    N + S could predict not only the OS and RFS in BCLC-B HCC patients undergoing hepatectomy, but also the recurrence patterns and RTDS in these patients. BCLC-B patients with N + S ≤ 10 had mild recurrence patterns, good RTDS and excellent OS similar to those in BCLC-A MNHCC patients.

    Research conclusions

    N + S can be used to select BCLC-B HCC patients who are more suitable for LR, and LR should be considered in BCLC-B patients with N + S ≤ 10.

    Research perspectives

    As a measure that can be easily obtained and calculated in clinical practice, N + S can help with the clinical decision-making in the treatment of BCLC-B HCC patients.

    FOOTNOTES

    Author contributions:Hu XS performed the research and wrote the paper; Yang HY performed the follow-up; Leng C designed the research and supervised the report; Zhang ZW provided clinical advice and supervised the report; and all authors read and approved the final version.

    Institutional review board statement:This study was reviewed and approved by the Ethics Committee of the Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology (Approval No. TJIRB20210918).

    Informed consent statement:Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.

    Conflict-of-interest statement:All the authors report no relevant conflicts of interest for this article.

    Data sharing statement:No additional data are available.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

    Country/Territory of origin:China

    ORCID number:Xin-Sheng Hu 0000-0002-0863-7909; Hui-Yuan Yang 0000-0003-0877-656X; Chao Leng 0000-0002-5391-651X; Zhi-Wei Zhang 0000-0002-4679-2598.

    S-Editor:Liu GL

    L-Editor:A

    P-Editor:Liu GL

    很黄的视频免费| 一级毛片精品| 一区二区三区激情视频| 亚洲国产精品sss在线观看 | 日韩欧美一区视频在线观看| 国产男女超爽视频在线观看| 无人区码免费观看不卡| 脱女人内裤的视频| 久久婷婷成人综合色麻豆| 午夜免费观看网址| 大香蕉久久成人网| 国产成人av激情在线播放| 一级黄色大片毛片| 1024香蕉在线观看| 一区二区三区精品91| 精品午夜福利视频在线观看一区| 亚洲专区字幕在线| 精品一区二区三卡| 18禁美女被吸乳视频| 99热网站在线观看| 韩国av一区二区三区四区| 亚洲全国av大片| 高清视频免费观看一区二区| 久久久国产成人免费| 最新美女视频免费是黄的| 亚洲色图av天堂| 日韩 欧美 亚洲 中文字幕| 免费观看人在逋| 亚洲欧美激情综合另类| 一本大道久久a久久精品| av天堂在线播放| 亚洲男人天堂网一区| 最新的欧美精品一区二区| 亚洲国产中文字幕在线视频| 国产精品亚洲一级av第二区| 一进一出好大好爽视频| 午夜精品在线福利| 久久国产亚洲av麻豆专区| 久久婷婷成人综合色麻豆| 99精品欧美一区二区三区四区| 麻豆av在线久日| 欧美中文综合在线视频| 在线观看免费视频日本深夜| 日本精品一区二区三区蜜桃| 免费在线观看黄色视频的| 久久国产精品人妻蜜桃| ponron亚洲| 久久香蕉国产精品| 久9热在线精品视频| xxxhd国产人妻xxx| ponron亚洲| 亚洲精品粉嫩美女一区| 这个男人来自地球电影免费观看| 人人妻人人澡人人看| 视频区欧美日本亚洲| 国产淫语在线视频| 国产av精品麻豆| 男女免费视频国产| 超色免费av| 国产精品久久视频播放| 欧美精品一区二区免费开放| 国产激情久久老熟女| 99国产精品99久久久久| 婷婷丁香在线五月| 久久ye,这里只有精品| 一级毛片高清免费大全| 97人妻天天添夜夜摸| videos熟女内射| 精品乱码久久久久久99久播| 黄色女人牲交| 国产精品一区二区在线观看99| 国产精品自产拍在线观看55亚洲 | 午夜精品在线福利| 正在播放国产对白刺激| av不卡在线播放| 午夜福利影视在线免费观看| 亚洲专区中文字幕在线| 黄色女人牲交| 欧美日韩亚洲综合一区二区三区_| 电影成人av| 国产成人av教育| 热re99久久国产66热| 亚洲 国产 在线| 国产一区二区三区综合在线观看| 两人在一起打扑克的视频| 欧美乱色亚洲激情| 两个人免费观看高清视频| 久久天躁狠狠躁夜夜2o2o| av天堂久久9| 在线观看www视频免费| 久久天堂一区二区三区四区| 免费在线观看黄色视频的| 色播在线永久视频| 精品一品国产午夜福利视频| 欧美成狂野欧美在线观看| 免费在线观看日本一区| 无遮挡黄片免费观看| 日本a在线网址| 人妻久久中文字幕网| 成年版毛片免费区| 亚洲av成人av| 国产黄色免费在线视频| 看免费av毛片| 在线观看一区二区三区激情| 一级片免费观看大全| 欧美大码av| 国产视频一区二区在线看| 在线免费观看的www视频| 欧美精品一区二区免费开放| 午夜福利影视在线免费观看| 久久精品国产清高在天天线| 99久久国产精品久久久| 亚洲午夜精品一区,二区,三区| 80岁老熟妇乱子伦牲交| 成人手机av| 国产精品一区二区免费欧美| 国产在线一区二区三区精| 久久人妻福利社区极品人妻图片| 高清av免费在线| 一级黄色大片毛片| 久久国产精品大桥未久av| 久久久久国产一级毛片高清牌| 国产成+人综合+亚洲专区| 精品一区二区三区视频在线观看免费 | 久久狼人影院| 啦啦啦 在线观看视频| 久久天躁狠狠躁夜夜2o2o| 亚洲国产中文字幕在线视频| 欧美 亚洲 国产 日韩一| 亚洲 国产 在线| 久久天堂一区二区三区四区| 日韩三级视频一区二区三区| 51午夜福利影视在线观看| 欧美精品一区二区免费开放| 老司机福利观看| 脱女人内裤的视频| 免费日韩欧美在线观看| 欧美亚洲日本最大视频资源| 午夜福利欧美成人| 亚洲成av片中文字幕在线观看| 日本a在线网址| 在线观看日韩欧美| 久久影院123| www日本在线高清视频| 国产精品影院久久| 男女免费视频国产| xxxhd国产人妻xxx| 国产精品香港三级国产av潘金莲| 欧美日韩福利视频一区二区| 美女国产高潮福利片在线看| 亚洲精品国产精品久久久不卡| 欧美黄色淫秽网站| 欧美日韩黄片免| 久久久久久久午夜电影 | 99久久99久久久精品蜜桃| 国产在线观看jvid| 国产熟女午夜一区二区三区| 曰老女人黄片| 成人免费观看视频高清| 在线播放国产精品三级| 亚洲 国产 在线| 在线看a的网站| 最新美女视频免费是黄的| 嫩草影视91久久| 久久精品国产亚洲av高清一级| 丰满人妻熟妇乱又伦精品不卡| 国产成人欧美| 夜夜爽天天搞| 色播在线永久视频| 黄片小视频在线播放| 99久久国产精品久久久| 久热爱精品视频在线9| 天堂√8在线中文| 国产97色在线日韩免费| 亚洲精品国产区一区二| 大型av网站在线播放| 国产成人av激情在线播放| 男女午夜视频在线观看| 老鸭窝网址在线观看| 黄色怎么调成土黄色| videos熟女内射| 又大又爽又粗| 在线观看舔阴道视频| 日韩欧美一区视频在线观看| e午夜精品久久久久久久| 一级a爱视频在线免费观看| 亚洲精品粉嫩美女一区| 久久久久精品国产欧美久久久| 12—13女人毛片做爰片一| 日韩欧美免费精品| 日日夜夜操网爽| 一级a爱片免费观看的视频| 大香蕉久久成人网| 曰老女人黄片| 国产精品.久久久| 人妻久久中文字幕网| 999精品在线视频| 丝袜美腿诱惑在线| 精品少妇久久久久久888优播| 午夜福利视频在线观看免费| 中文字幕人妻熟女乱码| 亚洲五月色婷婷综合| 国产亚洲欧美在线一区二区| 中文字幕最新亚洲高清| 啦啦啦免费观看视频1| 香蕉国产在线看| 美国免费a级毛片| 亚洲,欧美精品.| x7x7x7水蜜桃| 12—13女人毛片做爰片一| 最近最新中文字幕大全免费视频| 精品卡一卡二卡四卡免费| 80岁老熟妇乱子伦牲交| 少妇的丰满在线观看| 久久久久久免费高清国产稀缺| 91av网站免费观看| 看片在线看免费视频| av在线播放免费不卡| 欧美人与性动交α欧美精品济南到| 欧美 亚洲 国产 日韩一| 一二三四社区在线视频社区8| 国产单亲对白刺激| www.自偷自拍.com| 午夜精品在线福利| 老司机在亚洲福利影院| 亚洲av电影在线进入| 正在播放国产对白刺激| 国产又色又爽无遮挡免费看| 国产成人免费观看mmmm| 纯流量卡能插随身wifi吗| 国产精品久久久久久人妻精品电影| 亚洲 欧美一区二区三区| 成年动漫av网址| 女警被强在线播放| 变态另类成人亚洲欧美熟女 | 日本精品一区二区三区蜜桃| 国产精品欧美亚洲77777| 国产深夜福利视频在线观看| 午夜精品在线福利| 亚洲精品一卡2卡三卡4卡5卡| 免费高清在线观看日韩| 精品国产乱子伦一区二区三区| 久久国产精品男人的天堂亚洲| 69精品国产乱码久久久| 国产亚洲av高清不卡| 中文字幕人妻丝袜制服| 色播在线永久视频| 国产精品欧美亚洲77777| 精品人妻1区二区| 在线观看免费日韩欧美大片| 国产精品98久久久久久宅男小说| 亚洲av日韩在线播放| 久久午夜综合久久蜜桃| 日韩精品免费视频一区二区三区| 久久久久久亚洲精品国产蜜桃av| 999精品在线视频| 国产精品久久久久久人妻精品电影| 色综合婷婷激情| 国产精品免费一区二区三区在线 | 日韩制服丝袜自拍偷拍| 青草久久国产| 亚洲熟女毛片儿| 一夜夜www| 日日爽夜夜爽网站| 亚洲久久久国产精品| 久久久国产一区二区| 国产深夜福利视频在线观看| 久久性视频一级片| 麻豆乱淫一区二区| 一夜夜www| 成人精品一区二区免费| 午夜福利一区二区在线看| 久久久精品国产亚洲av高清涩受| 国产在视频线精品| 亚洲少妇的诱惑av| 美女高潮到喷水免费观看| 在线观看免费午夜福利视频| 黄色毛片三级朝国网站| 国产在线一区二区三区精| 黄色视频,在线免费观看| 国产单亲对白刺激| 97人妻天天添夜夜摸| 99热只有精品国产| 在线av久久热| 999精品在线视频| 午夜福利在线免费观看网站| 欧美另类亚洲清纯唯美| 女人被躁到高潮嗷嗷叫费观| 久久亚洲真实| 在线国产一区二区在线| 久久中文看片网| 狂野欧美激情性xxxx| 丝袜在线中文字幕| 欧美激情高清一区二区三区| 法律面前人人平等表现在哪些方面| 麻豆乱淫一区二区| 欧美日本中文国产一区发布| 久久精品国产99精品国产亚洲性色 | 国产午夜精品久久久久久| 午夜久久久在线观看| 亚洲av成人不卡在线观看播放网| 麻豆av在线久日| 久久精品亚洲精品国产色婷小说| 亚洲精品美女久久久久99蜜臀| 亚洲第一欧美日韩一区二区三区| ponron亚洲| 亚洲一区二区三区欧美精品| 在线观看舔阴道视频| 亚洲精品美女久久久久99蜜臀| 国产精品免费大片| 日韩制服丝袜自拍偷拍| 一区二区三区精品91| 国产免费男女视频| 亚洲成av片中文字幕在线观看| 少妇的丰满在线观看| 日韩中文字幕欧美一区二区| 极品教师在线免费播放| 男女高潮啪啪啪动态图| 亚洲精品在线美女| 99精国产麻豆久久婷婷| 正在播放国产对白刺激| 精品人妻1区二区| 18在线观看网站| 搡老熟女国产l中国老女人| av视频免费观看在线观看| 免费在线观看黄色视频的| 黑人巨大精品欧美一区二区mp4| 69av精品久久久久久| 中文字幕精品免费在线观看视频| 国产一区二区三区在线臀色熟女 | 天天躁夜夜躁狠狠躁躁| 欧美精品人与动牲交sv欧美| 成人精品一区二区免费| 亚洲av日韩精品久久久久久密| svipshipincom国产片| 国产成人欧美| 欧美成狂野欧美在线观看| 欧美成人午夜精品| av网站免费在线观看视频| 欧美性长视频在线观看| 18禁美女被吸乳视频| 国产成+人综合+亚洲专区| 亚洲性夜色夜夜综合| 男男h啪啪无遮挡| 日本黄色日本黄色录像| 亚洲色图综合在线观看| 啦啦啦 在线观看视频| 怎么达到女性高潮| 亚洲精品粉嫩美女一区| 美女福利国产在线| 久久国产精品大桥未久av| 在线观看免费高清a一片| 19禁男女啪啪无遮挡网站| xxxhd国产人妻xxx| 女人久久www免费人成看片| 久久青草综合色| 亚洲av成人av| 91精品国产国语对白视频| 大香蕉久久网| 午夜日韩欧美国产| 大陆偷拍与自拍| 亚洲av片天天在线观看| 国产有黄有色有爽视频| 国产精品久久久久成人av| 成在线人永久免费视频| 亚洲成人手机| 欧美激情高清一区二区三区| 欧美国产精品va在线观看不卡| 91av网站免费观看| 国产精品国产高清国产av | 国产一区二区三区视频了| 一区二区三区精品91| 日本黄色视频三级网站网址 | 国产在线一区二区三区精| 美女 人体艺术 gogo| 国产在线一区二区三区精| 极品人妻少妇av视频| 欧美+亚洲+日韩+国产| bbb黄色大片| 嫩草影视91久久| 精品一区二区三区四区五区乱码| 色在线成人网| 婷婷丁香在线五月| 国产精品久久久人人做人人爽| 日韩欧美在线二视频 | 国产激情欧美一区二区| 欧美日韩中文字幕国产精品一区二区三区 | 久久久国产精品麻豆| 国产99久久九九免费精品| 国产欧美亚洲国产| 色播在线永久视频| 一夜夜www| 亚洲一区中文字幕在线| 一边摸一边抽搐一进一小说 | x7x7x7水蜜桃| av中文乱码字幕在线| 久久久久久亚洲精品国产蜜桃av| 欧美在线黄色| 久久久久精品国产欧美久久久| 国产一卡二卡三卡精品| 黄色怎么调成土黄色| 黄色视频不卡| 久久精品国产综合久久久| 国产精品av久久久久免费| 成人永久免费在线观看视频| 亚洲一码二码三码区别大吗| 在线观看66精品国产| 18在线观看网站| 999久久久精品免费观看国产| 一级作爱视频免费观看| 国产男靠女视频免费网站| 久久久国产成人精品二区 | 69av精品久久久久久| 国产精品免费视频内射| 如日韩欧美国产精品一区二区三区| 亚洲精品中文字幕在线视频| 午夜精品国产一区二区电影| 精品国产一区二区久久| 村上凉子中文字幕在线| 多毛熟女@视频| 久久中文看片网| xxxhd国产人妻xxx| 天天添夜夜摸| 欧美日韩瑟瑟在线播放| 亚洲人成电影观看| 18禁观看日本| 可以免费在线观看a视频的电影网站| 免费少妇av软件| 成年女人毛片免费观看观看9 | 欧美黄色淫秽网站| 国产主播在线观看一区二区| 亚洲情色 制服丝袜| 亚洲熟妇中文字幕五十中出 | av线在线观看网站| 成人三级做爰电影| 1024香蕉在线观看| 国产1区2区3区精品| 久久中文字幕人妻熟女| 欧美不卡视频在线免费观看 | 久久人妻av系列| 捣出白浆h1v1| 亚洲一区二区三区不卡视频| a级毛片在线看网站| 欧美国产精品va在线观看不卡| 天天添夜夜摸| 多毛熟女@视频| 国产人伦9x9x在线观看| 亚洲伊人色综图| 亚洲熟女精品中文字幕| 中文字幕精品免费在线观看视频| 免费人成视频x8x8入口观看| 午夜两性在线视频| 久久久精品国产亚洲av高清涩受| 午夜福利欧美成人| 黄色a级毛片大全视频| 色94色欧美一区二区| 老司机深夜福利视频在线观看| 亚洲五月天丁香| 精品一区二区三区视频在线观看免费 | 亚洲成av片中文字幕在线观看| 欧美性长视频在线观看| 交换朋友夫妻互换小说| 国产精品久久久久久精品古装| 人人妻人人澡人人看| 一级a爱片免费观看的视频| 国产人伦9x9x在线观看| 亚洲中文av在线| 99国产精品一区二区三区| 国产黄色免费在线视频| 18禁观看日本| 一级片'在线观看视频| 精品乱码久久久久久99久播| 亚洲午夜理论影院| av超薄肉色丝袜交足视频| 欧美亚洲日本最大视频资源| 欧美黄色淫秽网站| 国产91精品成人一区二区三区| 国产激情欧美一区二区| 久久精品国产亚洲av高清一级| 下体分泌物呈黄色| 久久午夜亚洲精品久久| 亚洲成人免费av在线播放| 法律面前人人平等表现在哪些方面| 91精品三级在线观看| 欧美乱码精品一区二区三区| 中国美女看黄片| 久久久久久人人人人人| 777米奇影视久久| 欧美老熟妇乱子伦牲交| 91在线观看av| 免费看十八禁软件| 黑人巨大精品欧美一区二区蜜桃| 日韩欧美在线二视频 | 欧美 亚洲 国产 日韩一| 最新的欧美精品一区二区| 91字幕亚洲| 一级片'在线观看视频| 99精品欧美一区二区三区四区| 韩国av一区二区三区四区| 一级,二级,三级黄色视频| 纯流量卡能插随身wifi吗| 久久久久国产一级毛片高清牌| 亚洲,欧美精品.| 亚洲午夜理论影院| 久久精品成人免费网站| 丝瓜视频免费看黄片| 亚洲avbb在线观看| 欧美激情极品国产一区二区三区| 美女国产高潮福利片在线看| 在线观看日韩欧美| 国产淫语在线视频| 99精品在免费线老司机午夜| 满18在线观看网站| 老司机靠b影院| 少妇的丰满在线观看| 99热只有精品国产| 亚洲一区二区三区不卡视频| 大香蕉久久成人网| 日韩成人在线观看一区二区三区| 黑人欧美特级aaaaaa片| 久久中文字幕人妻熟女| 丰满饥渴人妻一区二区三| 操美女的视频在线观看| 亚洲第一青青草原| 无限看片的www在线观看| 国产精华一区二区三区| 日韩成人在线观看一区二区三区| 亚洲在线自拍视频| 免费女性裸体啪啪无遮挡网站| 激情视频va一区二区三区| e午夜精品久久久久久久| 亚洲精品一二三| 91在线观看av| 在线观看免费日韩欧美大片| 波多野结衣av一区二区av| 久久久久久久久免费视频了| 一夜夜www| 老汉色∧v一级毛片| 91麻豆av在线| 国产午夜精品久久久久久| 欧美日韩av久久| 99久久国产精品久久久| 一进一出好大好爽视频| 搡老熟女国产l中国老女人| 黄片大片在线免费观看| 在线视频色国产色| 91老司机精品| 亚洲七黄色美女视频| 热re99久久精品国产66热6| 成年女人毛片免费观看观看9 | 成人影院久久| 日韩欧美免费精品| 美女视频免费永久观看网站| 欧美成人免费av一区二区三区 | 黄色丝袜av网址大全| 国产精品自产拍在线观看55亚洲 | x7x7x7水蜜桃| 18禁国产床啪视频网站| 欧美人与性动交α欧美软件| tocl精华| 99re在线观看精品视频| 一级毛片高清免费大全| 丝袜人妻中文字幕| 国产亚洲精品第一综合不卡| 精品久久久久久久久久免费视频 | 欧美精品一区二区免费开放| 国产一区在线观看成人免费| 丁香六月欧美| 亚洲一区二区三区欧美精品| 亚洲美女黄片视频| 亚洲精品久久午夜乱码| 精品福利永久在线观看| 国产深夜福利视频在线观看| 最新美女视频免费是黄的| 一夜夜www| 三上悠亚av全集在线观看| 国产成人啪精品午夜网站| 亚洲av电影在线进入| 天堂俺去俺来也www色官网| 中出人妻视频一区二区| 五月开心婷婷网| 国产视频一区二区在线看| 久久久国产成人精品二区 | 国产极品粉嫩免费观看在线| av视频免费观看在线观看| av电影中文网址| 麻豆国产av国片精品| 两个人免费观看高清视频| 好看av亚洲va欧美ⅴa在| 91国产中文字幕| 国产淫语在线视频| 精品国产国语对白av| 午夜精品在线福利| 国产高清激情床上av| 美国免费a级毛片| 久久久国产成人免费| 国产蜜桃级精品一区二区三区 | 免费看十八禁软件| 国产成人系列免费观看| 日日摸夜夜添夜夜添小说| 亚洲精华国产精华精| 无遮挡黄片免费观看| 亚洲精品av麻豆狂野| 国产成人影院久久av| 一级a爱片免费观看的视频| 成人精品一区二区免费| 久久性视频一级片| 日韩精品免费视频一区二区三区| 亚洲欧美一区二区三区久久| 成人黄色视频免费在线看| 精品人妻在线不人妻| 一本大道久久a久久精品| 日韩有码中文字幕| 亚洲视频免费观看视频| 欧美国产精品va在线观看不卡|